Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters New Licensing Agreement, Strengthens Business Model
Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio The company out-licenses disruptive delivery technology, giving licensees access to existing patents Lexaria entered into a new beverage license agreement with a California-based cannabis firm The company recently announced four new appointments to its scientific advisory board Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a drug-delivery platform innovator with existing cannabinoid licensing agreements in Canada and the United States, as well as internationally. By out-licensing disruptive delivery technology DehydraTECH, the company has created a strong, revenue-generating business model and a growing patent portfolio. At…